B Cell Acute Lymphoblastic Leukaemia clinical trials

Explore recruiting b cell acute lymphoblastic leukaemia clinical trials.

Recruiting b cell acute lymphoblastic leukaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Acute Lymphoblastic Leukaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Germany, Italy, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia

Spain, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

B Cell Acute Lymphoblastic Leukaemia trials by city

B Cell Acute Lymphoblastic Leukaemia in Toronto B Cell Acute Lymphoblastic Leukaemia in Vancouver B Cell Acute Lymphoblastic Leukaemia in Montreal B Cell Acute Lymphoblastic Leukaemia in Calgary B Cell Acute Lymphoblastic Leukaemia in Edmonton B Cell Acute Lymphoblastic Leukaemia in Ottawa B Cell Acute Lymphoblastic Leukaemia in Winnipeg B Cell Acute Lymphoblastic Leukaemia in Quebec City B Cell Acute Lymphoblastic Leukaemia in Hamilton B Cell Acute Lymphoblastic Leukaemia in Kitchener B Cell Acute Lymphoblastic Leukaemia in London B Cell Acute Lymphoblastic Leukaemia in Halifax B Cell Acute Lymphoblastic Leukaemia in New York B Cell Acute Lymphoblastic Leukaemia in Los Angeles B Cell Acute Lymphoblastic Leukaemia in Chicago B Cell Acute Lymphoblastic Leukaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease